ExoMira Medicine
The Mission of ExoMira Medicine is to establish innovative, unique “Exotic Miracles” pipelines for targeted immunotherapy in cancer, viral infections, and other diseases with investigator new drugs (IND) for clinical trials. Our top priority is to create multi-line exotic cancer immunotherapies with the flagship product USP22 inhibitors, second-line human therapeutic antibodies, and third line next generation exosome biologics.
- (1) Strategize immunotherapeutic small compounds to simultaneously target both solid tumor cells and regulatory T cells with our flagship USP22 inhibitors (one stone-two birds).
- (2) Develop human antibodies blocking the drivers of circulating tumor stem cells with aritificial intelligence (AI)-guide screening, redesign, and optimization.
- (3) Engineer anti-cancer exosomes delivering neoantigen vaccines and small compounds to specifically target primary tumors and metastases. Develop anti-viral exosomes with neutralizing receptors at 100x efficacy than soluble counterparts to combat and neutralize broad variants and future merging corona viruses
USP22 relevant publications: 1. CRISPR screen in regulatory T cells reveals modulators of Foxp3. (Nature 2020). 2. A deubiquitination module essential for Treg fitness in the tumor microenvironment. (Sci Adv, 2022). 3. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development.(Mol Cell, 2012). 4. Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. (Cell Discov, 2015).
Publications related to anti-PODxL, anti-circulating tumor stem cell therapeutics, and exosome biologics: 5. Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer. (Cancer Discovery, 2023). 6. Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. (Cancer Discovery, 2019) 7. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. (Nature Commu, 2021) 8. Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. (eLife, 2023) 9. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. (Nature Commu, 2022)
News
The Exomira Medicine-Northwestern University team proudly presented their multi-line inventions and dual-targeting onco-immunotherpy technologies at Chicago Biomedical Consortium Biocapital Summit at Fulton Market, Chicago, IL (November 02, 2023)
Congratulations to ExoMira CSO Dr. Andrew Hoffmann and the team under the supervision of ExoMira cofounders Drs. Fang and Liu at Northwestern University published the single-cell RNA seq research article on COVID-19 immunity in Clinical Immunology (05-17-2023)
ExoMira co-founder Dr. Huiping Liu, Associate Professor of Pharmacology and Medicine (Hematology/Oncology) at Northwestern University was inducted as an elected member to American Society for Clinical Investigation (ASCI) (April 2023)
New Chan Zuckerberg Biohub Chicago will become a neighbor of ExoMira Medicine C/O Portal Innovations at the Fulton Labs, with a new mission to engineer technologies to measure human biology, understand inflammation and the immune System underlying many diseases (April, 2023).
ExoMira co-founders Drs. Huiping Liu and Deyu Fang at Northwestern University received American Cancer Society Cancer Stem Cell Consortium Team Grant (5-year support), congratulations ! (Jan 2023)
On January 1st, 2023, ExoMira moved to Portal Innovations and joined the ecosystem of Biotech Hub (1375 W Fulton St, Market Floor 6, Chicago, IL).
July 2022
ExoMira receives NIH/NIAID funded RO1 sub award with Northwestern University.
August 2021
Co-founders received Chicago Biomedical Consortium Accelerator Award. Congratulations!
September 2021
Co-founders submitted a National Institute of Health Small Buisness Innovative Research (SBIR) grant on Exosome Medicine
September 6th 2021
ExoMira Medicine Website Launched
Contact
Email: info@exomira.com
Address: ExoMira C/O Portal Innovations, Floor 6, 1375 W. Fulton, Chicago, IL 60607